Kenvue stock holds near $19 after Brazil deal headlines
Published on 08/21/2026 at 20:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kenvue Inc. (US49177J1025) stock is trading near $19.16 as of August 20, 2026, while the company's latest quarter delivered $3.96 billion in revenue and $0.31 in adjusted EPS. The same update shows revenue rose 3.0% year over year and EPS missed consensus by $0.01, giving investors a cleaner read on how the consumer health group is pacing its turnaround.
Brazil asset sale adds a new angle
Recent market coverage points to a definitive agreement to sell Kenvue's feminine care business in Brazil to Essity for $284.0 million, a deal that sharpens the portfolio story even as the share price stays close to the high-teens. The transaction matters because it pairs a one-off cash event with a business already generating $3.96 billion in quarterly sales, and the latest consensus view in market data still centers on a hold rating and a $19.27 price target.
Quarterly numbers still set the tone
The August 6, 2026 quarter also showed a 10.76% net margin and 21.22% return on equity, while analysts are still modeling $1.14 in EPS for the current fiscal year. That combination leaves the stock priced at 21.75 times earnings with a $36.34 billion market cap, so the next move is still tied more to execution than to broad market multiples.
Read more
MarketBeat report on Kenvue earnings and holdings news
Product shelf
Kenvue's portfolio still leans on familiar consumer health names such as Zyrtec, which sits inside the company's broader mix of allergy, pain, skin health and oral care products. That range matters because the group's revenue base remains large enough for product-level changes and asset sales to show up quickly in reported results.
Shares stay close to the tape
Kenvue stock last traded at $19.16 on August 20, 2026, with a 52-week range of $14.02 to $21.78 and a market cap of $36.34 billion. The share price now sits much closer to the upper end of that band than the lower end, while the most recent quarter's 3.0% revenue growth keeps the focus on whether the next updates can extend that pattern.
Fact box
Company: Kenvue Inc.
ISIN: US49177J1025
Ticker: KVUE
Exchange: NYSE
Sector / Industry: Consumer health / Personal products
Index membership: S&P 500
